secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001576280-22-000091
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q3 revenue $117.4M (+24% YoY); cuts full-year revenue guidance to $440-450M
--------------------------------------------------------------------------------

- Q3 clinical test volume 32,400 (+42% YoY); biopharma tests 6,750 (+40% YoY).
- GAAP net loss per share -$1.58; non-GAAP -$1.18; Adj. EBITDA loss -$112.8M.
- Full-year 2022 revenue guidance lowered to $440-450M from $460-470M, citing challenging backdrop.
- FDA approved Guardant360 CDx as companion diagnostic for ENHERTU in HER2-mutant NSCLC.
- ECLIPSE readout and Shield PMA submission expected in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/0001576280-22-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/gh-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001576280-22-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer